CD8A and acute lymphoblastic leukemia: In contrast with the B-ALL CD4/CD8 ratio median of 0.6 (range, 0.3–1.9), the DLBCL products had an increased ratio of 2.3 (range, 0.5–3.2) (Figure 1H).